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ABSTRACT 
OBJECTIVE: To determine the prevalence and clinical correlates of anti-phospholipid 
antibodies (aPL), including anti-cardiolipin antibodies (aCL), lupus anti-coagulant (LA), anti-
β2-glycoprotein 1 (aβ2GP1) and anti-prothrombin (aPT) antibodies, in Black South African 
patients with systemic lupus erythematosus (SLE) 
METHODS: A cross-sectional study of 100 SLE patients in whom clinical characteristics, 
including features of the anti-phospholipid syndrome (APS), disease activity, and damage 
were documented, and sera tested for aCL, aβ2GP, and aPT of all isotypes, and LA. 
RESULTS: Positive aCL, aβ2GP1 and aPT and LA were found in 53, 84, 20, and 2 patients, 
respectively. Immunoglobulin (Ig)A aCL and IgG aβ2GP1 were the commonest aCL (49.1%) 
and aβ2GP1 (47%) isotypes, respectively.  IgA aβ2GP1 were associated with both a history of 
thrombosis alone (p<0.05) and a history of any clinical feature, thrombosis and/or 
spontaneous abortion of the APS (p<0.05); IgA aCL were associated with a history of any 
clinical APS event (p<0.05); and aβ2GPI of any isotype were associated with a history of 
arthritis (p<0.001).  
CONCLUSION: My findings provide further evidence that the screening for aβ2GP1 and IgA 
aCL isotype may improve the risk assessment for APS in SLE patients of African extraction.  
Further prospective studies are warranted to determine the clinical utility of these tests and to 
elucidate the genetic basis for increased IgA aPL response in SLE patients of African 
extraction.  
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1 INTRODUCTION 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by the 
presence of a variety of circulating autoantibodies, including those directed against 
phospholipids (aPL). Elevated levels of aPL are frequently, but not invariably, associated with 
the anti-phospholipid syndrome (APS), which manifests clinically as venous or arterial 
thrombosis and/or recurrent spontaneous abortions (1). The thrombophilic activity of aPL is 
mediated by binding to the natural anticoagulant β2-glycoprotein 1 (β2GP1), which inhibits 
prothrombinase activity of platelets and adenosine diphosphate (ADP)-induced platelet 
aggregation.  To date, the immunoglobulin (Ig)G and IgM isotypes of anticardiolipin antibody 
(aCL) and the lupus anticoagulant (LA) are the only aPL included in the classification criteria 
for APS (2).  An emerging issue is the clinical utility of the IgA isotype of aCL and antibodies 
of all isotypes directed against β2GP1 (aβ2GP1) and prothrombin (aPT) (3).  Some experts 
argue that, as APS patients are unlikely to be negative for both aCL (IgG and IgM) and LA, it 
is superfluous to test for aβ2GP1 (4) and IgA aCL (5).  The role of aPT as markers of 
thrombophilia in SLE appears to be even more tenuous, and is, at best, only partially 
supported by the published literature (6-8).   
 
The spectrum and prevalence of both clinical features and autoantibodies, including aPL, 
show considerable inter-ethnic variation, which, in part, may account for ethnic differences in 
morbidity and mortality in SLE.  The limited published experience from sub-Saharan Africa, 
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particularly South Africa, suggests that the prognosis of SLE is poor compared to Caucasian 
patients in industrialised countries (9). In addition, the prevalence of anti-RNP and anti-Smith 
(anti-Sm) antibodies in Black South Africans (BSA) has been found to be higher than that 
reported in Caucasians (10). 
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2 AIMS OF THE STUDY 
I undertook a cross-sectional study to determine 1) the prevalence of IgG, IgM and IgA 
isotypes of aCL, LA and the newer aPL (aβ2GP1 and aPT) in BSA patients with SLE and 2) 
their relationship with thrombotic events and/ or spontaneous abortions as well as other 
clinical features of SLE. The study was approved by the Ethics Committee of the Faculty of 
Health Sciences, University of the Witwatersrand. 
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3 PATIENTS AND METHODS 
3.1 Patients 
One hundred unselected BSA patients, fulfilling at least 4 of the 11 American College of 
Rheumatology (ACR) criteria for SLE (11) and attending a tertiary care Lupus Clinic at Chris 
Hani Baragwanath Hospital, were studied. Patients known to be HIV positive were excluded 
from the study as HIV infection can be associated with aPL (12).  Clinical and antinuclear 
antibody (ANA) results were obtained by a combination of a detailed history of pregnancy 
loss and thrombotic events, data extraction from case records, and clinical examination. 
Disease activity and damage were assessed using the systemic lupus erythematosus disease 
activity index (SLEDAI) (13) and systemic lupus international collaborating clinics 
(SLICC)/ACR damage score (14), respectively.  The clinical features of APS, thrombosis and 
spontaneous abortions, were defined according to the Sapporo classification criteria for APS 
(2). 
 
3.2 Laboratory Methods 
The indirect immunofluorescence assay was used to screen for ANA and anti-dsDNA using 
HEp2 cell line and Crithidia lucillae as substrate (Diagnostic and Technical Services, 
Johannesburg, South Africa), respectively. aPL, IgG, IgM and IgA isotypes of the aCL, 
aβ2GP1 and aPT were measured using commercial enzyme linked immunoabsorbent assay 
(ELISA) kits (Cheshire Diagnostics Ltd, Ellesmere Port, Cheshire, UK), and expressed in 
units, according to the manufacturers instructions.  For aPT the ELISA kit used was one 
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where human prothrombin was directly coated onto activated polystyrene plates. IgG, IgM 
and IgA aCL were expressed as GPL, MPL and APL units respectively, whereas aβ2GP1 and 
aPT were expressed as arbitrary ELISA units (AEU), according to the manufacturer’s 
instructions.  The upper limit of each of these tests was based on previously published work 
on 100 sera from the healthy controls of the same ethnic and geographic background (12).  
Thus, the upper limit of normal for IgG isotype of aCL, aβ2GP1 and aPT were16 GPL, 6.7 
and 13.8 AEU, for IgM isotype 9.6 MPL, 4.5 and 16 AEU, and for IgA isotype, 8.7 APL, 4.6 
and 13.5 AEU, respectively. Lupus anticoagulant (LA) was detected using both the kaolin 
clotting time (16) and dilute Russell’s viper venom time (RVVT) assays (Instrument 
Laboratories Spa. Milan, Italy).  
 
 
3.3 Statistical analysis 
The Mann-Whitney U-test was applied to compare antibody levels between patient 
subgroups. The χ2 test (with Yates’ correction) or, where indicated, Fisher’s exact test was 
used to compare frequencies of categorical variables between subgroups of patients. 
Statistical analysis was performed using Statistica v5.1 (StatSoft Inc) and Epinfo v6 software.  
A p-value <0.05 was defined as being significant. 
 
 
 
 
   6 
   
   
   
   
   
 
 4 RESULTS 
The mean (±SD) age and disease duration of the 97 female and 3 male patients were 38.5 
(11.3) and 4.8 (4.1) yrs, respectively. The cumulative frequencies of the key clinical features, 
as defined by the ACR classification criteria, were discoid rash and malar rash each in 40, 
arthritis in 62,  nephropathy in 28, neuropsychiatric disease in 11, leucopaenia in 41, 
thrombocytopaenia in 9, positive Coomb’s test in 19, positive ANA in 99 and anti-dsDNA 
antibodies in 47 patients.  The mean (±SD) SLEDAI and SLICC/ACR damage scores were 
5.2 (6.6) and 1.9 (1.4), respectively. Table 1 shows the 19 patients identified as having 
fulfilled the clinical criteria of APS: 5 had only thrombotic complications, 12 had only 
spontaneous abortions and 2 had both thrombotic complications and spontaneous abortions.  
At the time of the study, 50/89 (56.2%) patients were on chloroquine and 71/91 (78%) were 
on oral prednisone and/or on immunosuppressive agents, including azathioprine, methotrexate 
or cyclophosphamide.
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4.1 Prevalence and isotype distribution of antiphospholipid antibodies 
The prevalence and distribution of the aPL and their 3 isotypes are shown in Table 2.  Eighty 
six sera were positive for at least one aPL.  In only 2 out of 89 (2.2%) were the LA assays 
positive (11 samples lost or invalid due to laboratory error).  Positive aCL, aβ2GP1 and aPT 
were found in 53, 84, and 20 of the patients.  As the sole isotype, IgA was the commonest in 
26 (49%) of the aCL positive sera, whereas IgG was the most prevalent sole isotype in 39 
(47%) of the aβ2GP1 positive sera and 14 (70%) of the aPT positive sera. 
  
TABLE 2. Prevalence of IgG, IgM and IgA isotypes of aCL, aβ2GPI and aPT antibodies in 
100 Black South African SLE patients 
Isotype  aCL   aβ2GP1 aPT 
Total any  53   84  20  
IgG only  3  39  14 
IgM only  8  1  4 
IgA only  26  16  0 
IgG+IgM  3  1  1 
IgG+IgA  9  20  0 
IgM+IgA  3  1  0 
IgG+IgM+IgA 1  6  1 
 
 
   9 
   
   
   
   
   
 
4.2 Clinical correlates 
Analysis of aPL as continuous variables (Table 3), revealed that patients with a history of 
thrombosis had significantly increased IgA aCL and IgG aβ2GP1 levels compared to those 
without a history of thrombosis.  Patients with a history of any clinical APS event (thrombosis 
and/or spontaneous abortion) had increased aβ2GP1 IgG and IgA and aPT IgA levels 
compared to those without a history of an APS event.  Patients with a history of arthritis had 
increased IgG aCL and IgA aβ2GP1 levels compared to those without a history of arthritis.  
Patients with a history of mouth ulcers had decreased levels of IgA aPT compared to those 
without a history of mouth ulcers.  
 
TABLE 3. Clinical correlates with antiphospholipid antibodies as continuous variables 
    Median (IQ)  Median (IQ)   
Clinical feature  Present   absent   p value 
History of thrombosis n=7   n=94 
IgA aCL   7.7 (5.2, 11.2)  14.6 (7, 24.3)  <0.05 
IgG aβ2GPI    7.8 (5.8, 10.4)  12.6 (10.3, 12.8) <0.01 
 
History of any APS event n=19   n=82 
IgG aβ2GPI    7.6 (5.9, 10.2)  10.5 (7.2, 12.8) <0.05 
IgA aβ2GPI   3.5 (1.9, 6.6)  5.9 (3.3, 9.0)  <0.05 
IgA aPT     3.4 (2.3, 4.9)  4.7 (3.4, 7.5)  <0.05 
 
History of arthritis  n=62   n=39 
IgG aCL   7.5 (4.3, 11.4)  9.6 (6.1, 13.3)  <0.05  
IgA aβ2GPI   3 (1.7, 5.4)  4.7 (2.4, 9)  <0.05 
 
History of mouth ulcers n=   n= 
IgA aPT   4 (2.6, 5.9)  3 (2, 3.5)  <0.02 
Values are median (IQ); IQ – 25, 75 interquartile values 
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Analysis of aPL as categorical variables (Table 4) showed that IgA aβ2GP1 were associated 
with both a history of thrombosis alone and a history any clinical APS event; IgA aCL were 
associated with a history of any clinical APS event; and aβ2GP1 of any isotype were 
associated with a history of arthritis.  No aPL associations with thrombocytopaenia, a 
common laboratory finding in APS, or the SLEDAI and SLICC/ACR damage scores were 
observed. 
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5 DISCUSSION  
 
The high prevalence of IgA aCL isotype, found in 39/100 of patients, is noteworthy.  It was 
the sole aCL isotype in 26 of patients and thus increased the overall sensitivity of aCL assay 
from 26% to 53%.  Other studies have shown a similar trend of higher prevalence of IgA aCL 
in SLE patients of African extraction.  Molina et al found that the IgA aCL was positive in all 
of the 26 Afro-Caribbean SLE patients studied and the sole isotype in 21 (81%) of patients 
(17).  In African Americans with SLE, IgA aCL has been found to be the most prevalent 
isotype occurring in 24% of patients (15). The pathological basis for this relatively high 
prevalence of in IgA aCL in patients of African extraction is not known.  Infection with 
human T cell leukaemia virus type 1 (HTLV-1) has been shown to induce an IgA aCL 
response in patients with tropical spastic syndrome (18). However, it is unlikely to account for 
this selective ethnic phenomenon, as HTLV-1 infections are not restricted to a specific ethnic 
group. From a clinical perspective, more importantly, IgA aCL levels were significantly 
raised in patients with a history of thrombosis and a positive IgA aCL result was associated 
with a history of any clinical APS event.  Lopez et al, in an American population where the 
ethnic group was not specified, showed that IgA aCL correlated better with clinical APS 
events than thrombocytopaenia and IgG and IgM aCL isotypes (19). Diri et al reported that 
IgA aCL was most frequent isotype in 7 out of 8 African American patients with APS (15).    
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Overall, aβ2GP1 were the commonest aPL, with the IgG isotype as the sole isotype in almost 
half the patients who were aβ2GP1 positive. My findings (tables 3 and 4) suggest that both the 
IgG and IgA isotypes may be of value in risk assessment for APS. As in the Afro- Americans, 
the isotype appears to be particularly associated with APS events in my study patients (15).  
Most studies suggest that, although aβ2GP1 are associated with APS events, testing for them 
has no additional value compared to the established aPL, aCL and LA (20-22).  However, in 
the present study, in almost a third (6/19) of the patients with clinical features of APS, aβ2GP1 
were the sole aPL. In a Canadian study, Bruce et al similarly found that aβ2GP1 were present 
in some patients with clinical features of APS who were negative for both aCL and LA (23).  
These findings suggest that although testing for aβ2GP1 isotypes does not supersede the 
established aPL, they might be of additional value in detecting patients with APS who are 
negative for aCL and LA.  
  
Unlike aβ2GP1, measuring aPT appears to be of little clinical value in the context of APS .  
Apart from the higher IgA aPT levels in patients with a history an APS event, I found no 
significant associations.  Moreover, in neither the overall cohort or in the subgroup of patients 
with a history of an APS event were aPT the sole positive aPL. While some studies have 
suggested measuring aPT might be of value in the context of APS (7, 24), several studies have 
shown otherwise (25-27). In a large study of primary and secondary APS, von Landenberg et 
al found that IgG aPT were particularly associated with early pregnancy loss (24). My 
findings are consistent with a recent Mexican study showing that both SLE and APS patients 
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with thrombosis had a higher prevalence of aPT, but no patients demonstrated aPT as the sole 
aPL (28). 
The strong association of a history of arthritis with aβ2GP1 is of interest, especially since it 
has not been reported previously.  Although elevated levels aPL have been found in other 
inflammatory arthritides such as rheumatoid arthritis (29) and juvenile idiopathic arthritis 
(30), it is not known whether these antibodies have a role in the pathogenesis of inflammatory 
arthritis. 
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6 LIMITATIONS 
Some of the limitations to a cross-sectional study of this nature include, firstly, that aPL levels 
are known to fluctuate over time (31, 32) and may be suppressed by immunosuppressive 
drugs. In the present study, more than three-quarters of the patients were on such agents. 
Second, the cross-sectional design of the study did not allow me to determine with certainty 
as to how many of the 19 patients with clinical features of APS met the Sapporo classification 
criteria for APS, according to which aPL have to be positive on at least 2 occasions 6 weeks 
apart.  
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7 CONCLUSION 
My findings provide further evidence that, at least in patients of African extraction, measuring 
IgA aCL and all isotypes of aβ2GP1 might be of value in risk assessment and diagnosis of 
APS.  Prospective studies are needed to confirm these findings.  The possible role of genetic 
factors, particularly class II HLA genes, in the expression of IgA aPL response in SLE 
patients of African extraction also needs to be elucidated.  
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